<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575406</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-14</org_study_id>
    <secondary_id>EudraCT 2007-004970-24</secondary_id>
    <nct_id>NCT00575406</nct_id>
  </id_info>
  <brief_title>Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma</brief_title>
  <acronym>NHL-14</acronym>
  <official_title>Multicentre Study to Determine the Cardiotoxicity of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone) Compared to R-COMP (Rituximab, Cyclophosphamide, Liposomal Doxorubicin, Vincristin and Prednisolone) in Patients With Diffuse Large B-Cell Lymphoma (NHL-14)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffuse large B-cell lymphoma is the most prevalent subgroup within malignant lymphoma.
      Clinical benefit has been shown for the treatment with cyclophosphamide, doxorubicin,
      vincristin and prednisolone (CHOP regimen); this could be further improved recently by the
      addition of rituximab (R-CHOP), a monoclonal antibody.

      Improved response and overall survival rates make it necessary to evaluate late toxicities of
      the therapy regimens. Cardiotoxicity is a known risk factor of specific chemotherapies, with
      7% patients being affected if doxorubicin cumulative doses are under 550mg/sqm. Retrospective
      data analyses indicate that this incidence of cardiotoxicity may be higher under combination
      chemotherapy. Liposomal doxorubicin has been shown to have lower cardiotoxic effects and at
      the same time equivalent or higher efficacy compared to conventional doxorubicin.

      The aim of this study is to evaluate alternative regimens for the treatment of diffuse large
      B-cell lymphoma, substituting liposomal doxorubicin (R-COMP) for conventional doxorubicin
      (R-CHOP).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of cardiotoxicity in the R-COMP arm versus R-CHOP</measure>
    <time_frame>Study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significance of serial NT-proBNP measurements for determination of anthracycline-dependent cardiotoxicity</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of evaluation with Haematopoietic Cell Transplantation Comorbidity Index (HCT-CI)</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Responses</measure>
    <time_frame>At end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Overall Survival at 3 and 5 yrs</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Event-free Survival at 3 and 5 yrs</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Progression-free Survival at 3 and 5 yrs</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cause-specific death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-COMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>i.v., 375 mg/m2, d0 or d1 of each treatment cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-COMP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>i.v., 750 mg/m2, d1 of each treatment cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-COMP</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>i.v., 50 mg/m2, d1 of each treatment cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal Doxorubicin</intervention_name>
    <description>i.v., 50 mg/m2, d1 of each treatment cycle</description>
    <arm_group_label>R-COMP</arm_group_label>
    <other_name>Myocet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristin</intervention_name>
    <description>i.v., 2mg, d1 of each treatment cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-COMP</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>p.o., 100mg, d1 - d5 of each treatment cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-COMP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, CD20 positive, diffuse large B-cell lymphoma (DLCL)

          -  measurable disease according to international criteria

          -  male or female

          -  age 18 years and above

          -  written informed consent

        Exclusion Criteria:

          -  myocardial infarction within 6 months prior to study entry

          -  cardiac insufficiency NYHA grade 3 or 4

          -  previous treatment with chemotherapy or radiotherapy

          -  CNS involvement of the disease

          -  positive for HIV

          -  WHO Performance Index 3 or 4

          -  secondary malignoma

          -  concurrent disease that prohibits chemotherapy

          -  known hypersensitivity towards the study interventions or their constituents

          -  neutropenia or thrombopenia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Fridrik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AKh Linz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6806</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Innsbruck/ Klinik für Innere Medizin</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus d. Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien / Haematologie u. Haemostaseologie</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

